Example: Heart Attack

Search clinical trials for: Muromonab-CD3

Total 139 results

NCT01287195

Completed

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Conditions: Ulcerative Colitis
NCT00027443

Completed

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Conditions: Myocarditis
NCT00619372

Unknown status

Oral OKT3 in Combination With Beta-D-Glucosylceramide

Conditions: Healthy
NCT01205087

Completed

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome

Conditions: Nonalcoholic Steatohepatitis
NCT00189345

Completed

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Conditions: Ovarian Cancer; Fallopian Tube Neoplasms; Peritoneal Neoplasms
NCT01459419

Unknown status

Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects

Conditions: Chronic Hepatitis C
NCT03291249

Withdrawn

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

Conditions: NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus)
NCT00450983

Terminated

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Conditions: Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes
NCT00004482

Completed

Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis

Conditions: Myocarditis; Giant Cell Myocarditis
NCT00129259

Completed

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Conditions: Diabetes Mellitus, Type 1
NCT00002482

Unknown status

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
NCT00630643

Completed

NI-0401 in Active Crohn's Disease

Conditions: Moderate to Severe Crohn's Disease
NCT00640497

Withdrawn

Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease

Conditions: Acute Graft Versus Host Disease
NCT00002572

Completed

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Conditions: Brain and Central Nervous System Tumors
NCT00002589

Unknown status

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Conditions: Kidney Cancer
NCT00521261

Withdrawn

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Conditions: Lymphoma
NCT02620865

Unknown status

Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Conditions: Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
NCT00239720

Terminated

PsA Treatment With hOKT3γ1 (Ala-Ala)

Conditions: Arthritis, Psoriatic
NCT00004022

Completed

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Conditions: Melanoma (Skin)
NCT00938626

Completed

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
NCT01420874

Active, not recruiting

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Conditions: Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer
NCT01123083

Completed

Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Conditions: Diabetes Mellitus, Type 1
NCT00678886

Completed

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1

Conditions: Diabetes Mellitus, Type 1
NCT01022138

Unknown status

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Conditions: Breast Cancer
NCT03406858

Recruiting

Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Conditions: Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7